Novartis Recalls Foradil Aerolizer Inhalation Powder Due to Stability Failure
Novartis is recalling Foradil Aerolizer inhalation powder because it failed a stability test for particle size distribution.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which by definition is unlikely to cause adverse health consequences. The issue is a stability specification failure without reported injuries or illnesses.
Plain-English summary
Novartis Pharmaceuticals Corp. is recalling Foradil Aerolizer (formoterol fumarate inhalation powder) 12 mcg per capsule. The recall involves 55,442 packs of the medication, which is distributed in New Jersey via one distributor. The specific lot number is F0082, with an expiration date of May 2015.
The recall was initiated because the product failed a stability specification. Specifically, an out-of-specification result was obtained for the Particle Size Distribution test during stability testing. This indicates that the physical characteristics of the powder may not meet the required standards over time.
Consumers and healthcare providers should stop using the affected product and contact their healthcare provider or pharmacist for guidance on alternative treatments. The product is a prescription-only medication intended for inhalation use.
The recalled product
- Product
- Foradil Aerolizer (formoterol fumarate inhalation powder) 12 mcg per capsule, 60 Capsules (Blister strips of 6) per pack. For inhalation use only, Rx only, Manufactured for: Merck Sharp & Dohme Corp., a subsidiary of MERCK & CO., INC. Whitehouse Station, NJ 08889. Manufactured
- Manufacturer
- Novartis Pharmaceuticals Corp.
- Category
- Drug — Inhalation Powder
- Hazard
- Affected units
- 55,442
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: F0082
- Exp May 2015
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 2 recalled by Novartis Pharmaceuticals Corp. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Novartis Pharmaceuticals Corp.
See all →- SevereNovartis Withdraws SANDIMMUNE Oral Solution Bottles Due to Crystallization
FDA (Drugs) · 2023-09-27
- CriticalNovartis Recalls Promacta Oral Suspension Due to Peanut Cross-Contamination
FDA (Drugs) · 2019-05-29
- LowNovartis Recalls Isopto Carpine Eye Drops for Impurity Failures
FDA (Drugs) · 2017-05-03
- ModerateNovartis Recalls Pilocarpine Hydrochloride Ophthalmic Solution for Impurity Failures
FDA (Drugs) · 2017-05-03
- LowNovartis Recalls Dexmethylphenidate HCl Extended-Release Capsules for Dissolution Failure
FDA (Drugs) · 2015-09-23
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCiclopirox shampoo recalled after failing impurity specifications at eighteen months
FDA (Drugs) · 2025-12-24